Clinical trials: Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)
The purpose of this study is to assess the safety and efficacy of Rodatristat Ethyl in pulmonary arterial hypertension (PAH) patients.
- Trial name
- NCT04712669
- Testing
- rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID
- Where
- 64 sites in United States, Austria and 15 more
- Volunteers
- 108 people
- Sponsor
- Altavant Sciences GmbH
Pulmonary Arterial Hypertension
Safety and Efficacy of Continued CS1 Treatment of Patients With Pulmonary Arterial Hypertension
CS1-004 will be an extension of the CS1-003 Study. The primary objective of the CS1-004 study is to evaluate long-term safety and tolerability of continued treatment with CS1.
- Trial name
- NCT06321705
- Testing
- CS1
- Where
- Sweden
- Sponsor
- Cereno Scientific AB
Sickle Cell Disease, Pulmonary Hypertension
Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell Disease
This study will examine whether the drug sildenafil can lower blood pressure in the pulmonary artery (the blood vessel that leads from the heart to the lungs) in patients with sickle cell disease and pulmonary hypertension (high…
- Trial name
- NCT00492531
- Testing
- Sildenafil
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 74 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Arterial Hypertension
Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension
This study will evaluate the safety, tolerability, and efficacy of imatinib mesylate in patients with pulmonary arterial hypertension
- Trial name
- NCT00477269
- Testing
- Imatinib mesylate
- Where
- 13 sites in United States, Austria and 2 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Hypertension
Database for Clinical and Anamnestic Data in Pulmonary Hypertension
Pulmonary hypertension (PH) is defined as a pulmonary arterial mean pressure (meanPAP) ≥ 25 mmHg measured in the right heart catheterization. There are different forms of PH defined in the classification of Dana Point 2008.
- Trial name
- NCT01607502
- Where
- Austria
- Volunteers
- 900 people
- Sponsor
- Medical University of Graz
Chronic Thromboembolic Pulmonary Hypertension
Change-a Multi-center Chronic Thromboembolic Pulmonary Hypertension （CTEPH） Database in China
The Change Database is a prospective, observational multi-center disease registry, which will collect data on patients with chronic thromboembolic pulmonary hypertension (CTEPH) in China.
- Trial name
- NCT05311072
- Testing
- pulmonary endarterectomy or balloon pulmonary angioplasty
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- China-Japan Friendship Hospital
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Rutgers University Study of the Genetics of Pulmonary Hypertension
The goal of this observational study is to learn more about how genes impact the risk of pulmonary hypertension. Anyone 18 or older living in the US is eligible, and a diagnosis of PH is NOT required.
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
- Trial name
- RUGCC-PH (NCT07217522)
- Testing
- Saliva sample, Health surveys
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Pulmonary Hypertension, Interstitial Lung Disease
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-211 (NCT05176951) and other lead-in studies of TPIP in participants with…
- Trial name
- NCT05649722
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 22 sites in Argentina, Australia and 5 more
- Volunteers
- 31 people
- Sponsor
- Insmed Incorporated
Pulmonary Arterial Hypertension
Riociguat in Triple Therapy for Pulmonary Arterial Hypertension in Real-World Practice
Pulmonary arterial hypertension is a rare and serious disease that can lead to heart failure and early death despite modern treatments.
- Trial name
- REAPPRAISED (NCT07374302)
- Volunteers
- 15 people
- Sponsor
- Caio Júlio César dos Santos Fernandes
Pulmonary Arterial Hypertension
TReatment Of Pulmonary HYpertension 1-US Study
The objective of this study is to assess the safety, performance and initial effectiveness of the TIVUS™ System when used for pulmonary artery denervation through subjective and objective change in clinical parameters and…
- Trial name
- TROPHY 1-US (NCT02835950)
- Testing
- Therapeutic Intra-Vascular UltraSound (TIVUS™) System
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- SoniVie Inc.
Pulmonary Arterial Hypertension
A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)
Researchers are looking for other ways to treat people in India with pulmonary arterial hypertension (PAH), also known as Group 1 pulmonary hypertension (PH).
- Trial name
- NCT07600723
- Testing
- Sotatercept, Background PAH Therapy
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
Infection, Heart Failure
Prediction of Patient Deterioration Using Machine Learning
This is a retrospective observational study drawing on data from the Brigham and Women's Home Hospital database. Sociodemographic and clinic data from a training cohort were used to train a machine learning algorithm to predict…
- Conditions
- Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT05045742
- Testing
- Traditional vital sign alarms versus the BioVitals Index vs the National Early Warning Score 2
- Where
- 2 sites in United States
- Volunteers
- 526 people
- Sponsor
- Brigham and Women's Hospital
Pulmonary Arterial Hypertension
Study of Cardiac MRI in the Follow up Assessment of Patients With PAH (EVITA)
Pulmonary arterial hypertension (PAH) is characterized by a progressive increase in pulmonary vascular resistance leading to right ventricular failure and eventually to death.
- Trial name
- EVITA (NCT02845518)
- Testing
- Cardiac magnetic resonance imaging (cMRI)
- Where
- France
- Volunteers
- 169 people
- Sponsor
- Central Hospital, Nancy, France
Pulmonary Arterial Hypertension
Pharmacokinetic Study of Sub-q and IV Treprostinil in Kids With Pulmonary Arterial Hypertension (PAH)
Abstract This is a multi-center, open-label pharmacokinetic (PK) study examining the relationship between the steady-state plasma concentration and dose of treprostinil delivered intravenously or subcutaneously in children with…
- Trial name
- PKRemodulin (NCT02318186)
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Jeffrey A. Feinstein
Pulmonary Arterial Hypertension
BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
This 6-month open label study will evaluate the long term safety of bosentan (via oxygen saturation) and efficacy (exercise capacity) in patients who have completed the BREATHE-5 study (PAH related to Eisenmenger physiology).
- Trial name
- NCT00367770
- Testing
- Tracleer®
- Where
- 17 sites in United States, Australia and 9 more
- Volunteers
- 37 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Selonsertib in Adults With Pulmonary Arterial Hypertension
The primary objective of this study is to evaluate the effect of selonsertib (GS-4997) on pulmonary vascular resistance (PVR), as measured by right heart catheterization (RHC) in adults with pulmonary arterial hypertension (PAH).
- Trial name
- ARROW (NCT02234141)
- Testing
- Selonsertib
- Where
- 46 sites in United States, Canada and 6 more
- Volunteers
- 151 people
- Sponsor
- Gilead Sciences
Pulmonary Arterial Hypertension
Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids.
Pulmonary arterial hypertension is a chronic disease of the lung blood vessels resulting in constriction and high pressures. Treatment is given with a variety of drugs including the prostanoid class (e.g.
- Trial name
- NCT00705588
- Testing
- Tadalafil, Vardenafil
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Rabin Medical Center
Hypertension, Diabetes
Development and Testing of a Sub-district Specific Model of 'Whole-of-government', and 'Whole-of-society' Approaches for the Prevention and Control of Non-communicable Diseases in a Sub-district of Bangladesh
Globally, non-communicable diseases (NCDs) are the leading cause of both mortality and morbidity. This intervention study aims to prevent and manage NCDs by adopting the World Health Organization's (WHO) comprehensive…
- Conditions
- Hypertension, Diabetes, Asthma, Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT06453382
- Testing
- Behavioural change modification, Screening, NCD related knowledge practice and attitude
- Where
- Bangladesh
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- BRAC University
Pulmonary Hypertension, Right Ventricular Outflow Tract Dysfunction
Feasibility of Non-invasive Hemodynamic Assessment by 5D Flow in Congenital Heart Disease
This study evaluates whether new flow parameters of the cardiac magnetic resonance imaging (MRI) allow evaluation of parameters for which usually invasive rigth-left heart catheterization are necessary.
- Conditions
- Pulmonary Hypertension, Right Ventricular Outflow Tract Dysfunction, Fontan Circulation
- Trial name
- NCT07742046
- Testing
- Right-left heart catheterization in magnetic resonance imaging (MRI)
- Where
- Switzerland
- Volunteers
- 130 people
- Sponsor
- Tobias Rutz
Pulmonary Arterial Hypertension
Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH
An Open-Label Long-Term Safety Study of Inhaled Nitric Oxide (iNO) for Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT02652429
- Testing
- Inhaled Nitric Oxide
- Where
- 17 sites in United States, Canada
- Volunteers
- 22 people
- Sponsor
- Bellerophon Pulse Technologies